Pulmatrix (NASDAQ:PULM) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

NASDAQ:PULM opened at $6.40 on Monday. The firm has a market capitalization of $23.36 million, a price-to-earnings ratio of -2.42 and a beta of 1.38. The company’s 50-day moving average is $6.52 and its two-hundred day moving average is $6.29. Pulmatrix has a 1-year low of $1.72 and a 1-year high of $10.40.

Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings results on Friday, March 21st. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter. Pulmatrix had a negative net margin of 96.51% and a negative return on equity of 45.97%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pulmatrix stock. Geode Capital Management LLC increased its stake in Pulmatrix, Inc. (NASDAQ:PULM) by 24.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 36,871 shares of the biotechnology company’s stock after acquiring an additional 7,290 shares during the quarter. Geode Capital Management LLC owned approximately 1.01% of Pulmatrix worth $257,000 at the end of the most recent quarter. 11.84% of the stock is owned by institutional investors and hedge funds.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.